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Abstract
Background: The amplification of oncogenes initiated by high-risk human papillomavirus (HPV) infection is an
early event in cervical carcinogenesis and can be used for cervical lesion diagnosis. We measured the genomic
amplification rates and the patterns of human telomerase RNA gene (TERC) and C-MYC in the liquid-based
cytological specimens to evaluate the diagnostic characteristics for the detection of high-grade cervical lesions.
Methods: Two hundred and forty-three residual cytological specimens were obtained from outpatients aged 25 to
64 years at Qilu Hospital, Shandong University. The specimens were evaluated by fluorescence in situ hybridization
(FISH) using chromosome probes to TERC (3q26) and C-MYC (8q24). All of the patients underwent colposcopic
examination and histological evaluation. A Chi-square test was used for categorical data analysis.
Results: In the normal, cervical intraepithelial neoplasia grade 1 (CIN1), grade 2 (CIN2), grade 3 (CIN3) and
squamous cervical cancer (SCC) cases, the TERC positive rates were 9.2%, 17.2%, 76.2%, 100.0% and 100.0%,
respectively; the C-MYC positive rates were 20.7%, 31.0%, 71.4%, 81.8% and 100.0%, respectively. The TERC and C-
MYC positive rates were higher in the CIN2+ (CIN2, CIN3 and SCC) cases than in the normal and CIN1 cases (p <
0.01). Compared with cytological analysis, the TERC test showed higher sensitivity (90.0% vs. 84.0%) and higher
specificity (89.6% vs. 64.3%). The C-MYC test showed lower sensitivity (80.0% vs. 84.0%) and higher specificity
(77.7% vs. 64.3%). Using a cut-off value of 5% or more aberrant cells, the TERC test showed the highest
combination of sensitivity and specificity. The CIN2+ group showed more high-level TERC gene copy number
(GCN) cells than did the normal/CIN1 group (p < 0.05). For C-MYC, no significant difference between the two
histological categories was detected (p > 0.05).
Conclusions: The TERC test is highly sensitive and is therefore suitable for cervical cancer screening. The C-MYC
test is not suitable for cancer screening because of its lower sensitivity. The amplification patterns of TERC become
more diverse and complex as the severity of cervical diseases increases, whereas for C-MYC, the amplification
patterns are similar between the normal/CIN1 and CIN2+ groups.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1308004512669913.
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Cervical cancer is widely recognized to be caused primarily
by persistent infection with high-risk human papilloma-
virus (HPV). The integration of the HPV genome into the
host genome results in the constitutive expression of the
oncoproteins E6 and E7, which combine with the tumor
suppressor genes P53 or RB to disrupt cell cycle regulation
and initiate the crucial step of tumorigenesis [1-3]. HPV
infection is necessary but not sufficient for cervical carci-
nogenesis. HPV infection is common and, in most cases, is
self-limiting and can be eradicated; only a minority of the
cases progress to cervical precancerous lesions. The con-
trast between the high rate of HPV infection and the low
rate of associated cervical cancer morbidity suggests that
additional genetic events are necessary for the malignant
progression of cervical lesions [4]. The amplification of
oncogenes is commonly observed in cervical precancerous
lesions according to the results of comparative genomic
hybridization (CGH) studies [5,6]. In contrast to chromo-
somal instability, oncogene amplification can occur even
in an otherwise chromosomally stable cell and is a fairly
early event in cervical carcinogenesis.
For cervical cancer screening, a single liquid-based
cytological examination is relatively insensitive, has poor
repeatability and often gives equivocal results. Used as a
complementary procedure, the Hybrid Capture 2 (HC2)
HPV DNA test is characterized by extremely high sensi-
tivity but relatively low specificity. In clinical practice,
high-grade lesions require immediate surgical treatment,
whereas low-grade lesions may be closely monitored at
defined intervals. This situation has prompted efforts to
discover other biomarkers with the potential for high
specificity as well as high sensitivity for the detection of
high-grade lesions and cervical cancers. The change of a
biomarker must be an early event in the process of cervi-
cal carcinogenesis. Oncogenes that are frequently ampli-
fied in precancerous lesions should be taken into
consideration.
The pattern of chromosomal imbalances in cervical can-
cer is conserved. We reviewed relevant literature and
found that TERC (3q26) and C-MYC (8q24) are the two
most frequently observed amplified oncogenes in cervical
precancerous lesions according to the results of CGH
studies [5,6]. TERC, the RNA component of human telo-
merase, is the most frequently observed amplified onco-
gene and is presumed to play a central role in cervical
carcinogenesis [5-8]. TERC amplification was observed in
35% of cervical intraepithelial neoplasia grade 3 (CIN3)
cases and in 72% of invasive cancers [6]. The C-MYC
(8q24) locus is the most commonly observed integration
site of the HPV genome [9-13]. C-MYC amplification is
frequently detected in precancerous cervical lesions with
HPV infection. C-MYC may promote the immortality of
the precancerous cells by directly activating the transcrip-
tion of telomerase reverse transcriptase (TERT) [14]. In a
study by Policht et al. (2010) [15], C-MYC positivity rates
in normal subjects, CIN1, CIN2, CIN3 and cancer patients
were 5%, 26%, 96%, 95% and 100%, respectively, and
increased in association with the severity of the histologi-
cal diagnosis. These biomarkers have great potential for
use as tools in routine cervical diagnostics, and researchers
have focused on the choice of test method and cut-off
value.
The aims of the present study were to explore the distri-
bution of the oncogene amplification patterns of TERC
and C-MYC among women undergoing liquid-based cyto-
logical examination during population-based screening,
and to compare the fluorescence in situ hybridization
(FISH) results with the underlying histology of the cytolo-
gical specimens at various cut-off values to assess the diag-
nostic characteristics of these biomarkers in the diagnosis
of CIN2+. Interphase FISH for TERC and C-MYC was
performed on residual liquid-based cytological specimens.
The ratios of aberrant cell count/observed cell count and
oncogene amplification patterns were recorded. All cases
underwent colposcopic examination and were histologi-
cally confirmed.
Materials and methods
Specimens
Residual PreservCyt (Cytyc) cytological specimens from
243 outpatients (aged 25 to 64 years) seen at Qilu Hospi-
tal, Shandong University (Jinan, Shandong, China)
between August 2010 and October 2011 were obtained.
One hundred and thirty-two cases that were negative for
intraepithelial lesion or malignancy (NILM), 50 cases of
atypical squamous cells of undetermined significance
(ASCUS), 21 cases of low-grade squamous intraepithelial
lesion (LSIL), 14 cases of atypical squamous cells that
cannot be excluded for high-grade squamous intraepithe-
lial lesion (ASC-H), 23 cases of high-grade squamous
intraepithelial lesion (HSIL) and 3 cases of squamous cell
carcinoma (SCC) were included. All of the 132 NILM
cases (including 84 HPV-positive cases and 48 HPV-
negative cases) and 55 cytologically abnormal cases
(ASCUS or worse; ASCUS+) were obtained from a large-
scale opportunistic screening program between August
2010 and February 2011 (detailed screening program
design see flow chart in Figure 1). To facilitate statistical
analysis of the amplification patterns, another 56 ASCUS
+ cases were recruited from February 2011 to October
2011. Patients who were confirmed to have histological
CIN and had undergone colposcopic examination or
treatment for cervical lesions were excluded from the
study. The study was approved by the ethics committee
of Qilu Hospital, Shandong University and performed in
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mens had been used previously for clinical purposes,
were no longer clinically necessary and were used for the
present study with the informed consent of the patients.
The results of liquid-based cytological analysis were clas-
sified according to the 2001 Bethesda System [16]. In
cases of controversial results, a consensus on the result
was reached by two cytopathologists. Colposcopic
Population-based screening 
Fifty-six residual cytological specimens 
from patients with cytological results of 
ASCUS+ were added to the present 
study. 
All of the 56 ASCUS+ cases underwent 
TERC FISH, C-MYC FISH, HC2 HPV 
DNA test, colposcopy and histological 
evaluation.
Liquid-based cytology
TERC FISH, C-MYC FISH and HC2 HPV DNA test 
If cytology, TERC FISH, C-MYC 
FISH or HC2 HPV DNA test result 
is abnormal 
Colposcopic examination; histological 
evaluation were performed with 
indications.  
132 NILM cases (including 84 HPV 
positive cases and 48 HPV negative 
cases) and 55 ASCUS+ cases were 
histologically-confirmed and were 
included in the present study. 
Histological normal  CIN2+
Follow-up: cytology, 
HPV testing, TERC 
FISH, C-MYC FISH, 
colposcopy and 
histological evaluation 
Routine follow-up 
CIN1 
Surgical treatment 
Figure 1 Flow chart of the study design.
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formed within 4 months for all cases, including normal
and dysplasia cases. The pathologists who evaluated the
biopsy specimens were unaware of the cytological results,
and any discrepancies were resolved by two pathologists.
The residual cytological specimens were stored at 4°C for
the FISH test. Each specimen was incubated with col-
lagen B and deionized water, fixed with methanol-acetic
acid, stored at -20°C and tested by FISH within 1 month.
Cervical cancer-specific FISH probe panel
The two most frequently amplified oncogenes detected
in cervical precancerous lesions in previous CGH stu-
dies, TERC and C-MYC, were evaluated by FISH in the
present study for their amplification patterns in cytologi-
cal specimens. The panel consisted of two groups: (i)
dual-color FISH probes for TERC (labeled with spec-
trum red) and centromere 3 (CEP3, labeled with green;
used to evaluate the amplification of arm vs. polyploidy);
(ii) C-MYC (labeled with red). All of the probes were
provided by GP Medical Technologies (Beijing, China).
Five to ten milliliters of cell preserved liquid from each
specimen was centrifuged to collect cells. The collected
cells were incubated with collagen B at 37°C for 20 min
and then with deionized water at 37°C for 30 min. The
treated cells were twice fixed in methanol-acetic acid
(3:1) for 10 min. The cell suspensions were then trans-
ferred to microscope slides by a dropper; one drop was
used for the TERC test, and another was used for the
C-MYC test. The slides were dried at 56°C for 30 min,
and the shape and number of cervical epithelial cells
were observed under a light microscope with a 10×
objective by limiting the light through the diaphragm.
Cell numbers of approximately 200 to 800 were used
because smaller cell numbers are not sufficient for eva-
luation and too many cells often clump together. The
slides were washed twice in 2 × SSC for 5 min, treated
with 0.1 M HCl for 10 min, digested with 0.02 mg/ml
pepsin/0.01 M HCl at 37°C for 10 min, fixed in 2.5%
formaldehyde/PBS for 10 min, dehydrated in an ethanol
series and air dried. The slides and probes were dena-
tured simultaneously at 75°C for 5 min followed by
hybridization in a wet box at 42°C for 16 h. The cover
slips were removed, and the slides were washed in 0.3%
NP-40/0.4 × SSC at 67°C for 2 min, in 0.1% NP-40/2 ×
SSC for 30 s and in 70% ethanol for 3 min. The slides
were counterstained with 4,6-diamidino-2-phenylindole
(DAPI) for 10-20 min, and then screened with a 40×
objective to observe the hybridization quality. Slides
were considered disqualified if more than 25% of the
cells were insufficiently hybridized. In this situation, we
transferred suspended cells onto the slides again and
repeated the hybridization procedure.
Signal enumeration
FISH images were acquired using an Olympus BX51
fluorescence microscope (Tokyo, Japan) that was con-
nected to a ProgRes Mfcool JENOPTIK camera (Jena,
Germany). Multilayer images were then acquired for all
of the probes in the probe panel using VideoTesT-FISH
2.0 software. The slides were screened with a 100×
objective through a DAPI filter to determine the cell
areas by starting at one corner of the slide and advan-
cing from one field of view to the next in an orderly
manner. We enumerated TERC signals through a red
filter and CEP3 signals through a green filter at one
slide and C-MYC signals through a red filter on another
slide. Several continuous visions were evaluated and the
signals from all cells in the visions were enumerated. At
least 100 nuclei for each probe were evaluated and the
proportion of abnormal cells was calculated [17,18].
Next, we rapidly screened ther e s i d u a la r e a s .I nm o s t
cases the ratio of aberrant cells to observed cells
remained stable. When small populations of aberrant
cells within a large cell population were detected, focal
precancerous lesions could not be ruled out. In these
cases, we enumerated several other visions including the
one with the aberrant cell crowd.
Normal diploid cells contain 2 signals of each probe in
a nucleus, and a 2:2 signal ratio of TERC to CEP3 indi-
cates a normal signal pattern. A cell was considered to be
chromosomally abnormal if either TERC or C-MYC
probe showed 3 or more signals per cell (Figure 2).
When two signals lay next to each other, they were con-
sidered to be a doublet if there was almost no space
between them and each signal was smaller than normal.
If there was apparent space between the two signals and
they had the same size as normal signals, they were
enumerated as two separate signals. A consensus diagno-
sis was made by two pathologists in cases of controversial
enumerations regarding doublets. The pathologists who
enumerated the signals were unaware of the cytological
and histological results. The amplification patterns of
TERC and C-MYC for each patient were recorded using
a manual counter and then taken together. The results
included ratios of abnormal cell count/observed cell
count and hybridization patterns of aberrant cells, e.g.,
3/100, 3-2 × 3.
Statistical analysis
A Chi-square test was used for 2 × 2 table analysis of the
categorical data. A Z-test was used to assess whether the
calculated rates of two groups were significantly different.
Statistical significance was set at P value less than 0.05.
Youden’s index (Y = sensitivity + specificity - 1) was used
to evaluate the combined sensitivity and specificity of the
diagnostic methods. Receiver operator characteristic
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evaluate the optimal cut-off value at different aberrant
cell percentages and gene copy number (GCN) for CIN2
+ diagnosis. DFI was calculated as [(1 - sensitivity)
2 +( 1-
specificity)
2]
1/2. The curves closet to the ideal values of
100% sensitivity and 100% specificity (top left corner of
Figure 2 Representative images of probe set TERC -CEP3 and C-MYC signals observed in cervical epithelial cells. A: Normal TERC-CEP3
signal pattern of 2-2 (patterns are described in the order TERC-CEP3). B: Normal C-MYC signal pattern with 2 signals in each nucleus. C: A 7-4
pattern cell of TERC-CEP3 hybridization is shown at the bottom. The cytological diagnosis was LSIL, whereas the histological diagnosis was CIN2.
D: A 4-signal cell of C-MYC hybridization is shown at the left. The cytological diagnosis was HSIL, but the histological diagnosis was CIN1. E: A 7-
7 signal pattern cell from a HSIL patient. The histological diagnosis was CIN3. F: Two 7-signal cells that lay next to each other in an HSIL patient.
The histological diagnosis was CIN3.
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provide the best combination of sensitivity and specifi-
city, giving the equal weight to each.
Results
Cut-off values from various cell percentages and GCNs of
the TERC test and the C-MYC test
ROC curves for various cell percentages and GCNs for
CIN2+ diagnosis were produced using the data from all
243 cases (Figure 3A), and the areas under the curves
(AUC) were calculated. The optimal cut-off value was ≥
5% aberrant cells of TERC among the cut-off values of cell
percentages and GCNs of TERC and C-MYC. Using this
cut-off value, the TERC test showed 90.0% sensitivity and
an ideal combination of sensitivity and specificity (You-
den’s index = 79.6%) in CIN2+ diagnosis. DFI curves for
different cell percentages and for different GCNs were
produced separately (Figure 3B, C). For the TERC test, the
cut-off value of ≥ 5% TERC gain cells (AUC = 0.9, DFI =
0.2) showed a higher combined sensitivity and specificity
than the cut-off value of TERC GCN ≥ 5 (AUC = 0.8,
DFI = 0.3). For the C-MYC test, the cut-off value of ≥ 3%
C-MYC gain cells (AUC = 0.8, DFI = 0.3) showed a higher
combined sensitivity and specificity than the cut-off value
of C-MYC GCN ≥ 4 (AUC = 0.7, DFI = 0.4). We chose ≥
5% TERC gain cells as the cut-off value of the TERC test
and ≥ 3% C-MYC gain cells as the cut-off value of the
C-MYC test for statistical analysis.
The association between TERC and C-MYC amplification
rates and cytopathological and histopathological
evaluations
The number of cases with TERC and C-MYC amplifica-
tions according to cytological diagnoses is shown in
Table 1. In the cytological diagnoses of NILM, ASCUS,
LSIL, ASC-H, HSIL and SCC, the TERC positive rates
were 8.3%, 20.0%, 52.4%, 64.3%, 91.3% and 100.0%,
respectively, and the C-MYC positive rates were 22.0%,
26.0%, 57.1%, 42.9%, 87.0% and 100.0%, respectively. Sig-
nificant differences were detected among normal
(NILM), low-grade lesions (ASC/LSIL) and high-grade
lesions (HSIL/SCC) for both TERC and C-MYC (p <
0.01). There were also significant differences between
LSIL or lower and HSIL or higher for both TERC and C-
MYC (p < 0.01). The number of cases with TERC and C-
MYC amplifications with different histological results is
shown in Table 2. For the histological diagnoses of nor-
mal, CIN1, CIN2, CIN3 and SCC, the TERC positive
rates were 9.2%, 17.2%, 76.2%, 100.0% and 100.0%,
respectively, and the C-MYC positive rates were 20.7%,
31.0%, 71.4%, 81.8% and 100.0%, respectively. The TERC
and C-MYC positive rates were similar between normal
and CIN1 but higher in CIN2+ than in CIN1 (p <0 . 0 1 ) .
Significant differences were also observed between CIN1/
lower and CIN2/higher (p < 0.01).
The association between FISH test positivity and cytolo-
gical/histological diagnosis is shown in Table 3. Of the 8
NILM cases with underlying CIN2+, 2 TERC+/CMYC +
cases, 1 TERC-/CMYC + case, 1 TERC+/CMYC- case and
4 TERC-/CMYC- cases were observed. For the 2 HSIL
cases with normal histological results, both TERC and C-
MYC tests were negative. For the 1 HSIL case with under-
lying CIN1, the cell percentages for the TERC test and the
C-MYC test were 15% and 12%, respectively, but the
amplification was at a low level (3-4 copies for the TERC
test and the C-MYC test).
Of the 243 total cases, 48 TERC+/C-MYC + cases
were detected, and 81.3% (39 of 48) of these cases
showed histologically confirmed CIN2+. Of the 17
TERC+/C-MYC- cases, 35.3% (6 of 17) showed CIN2+.
Of the 35 TERC-/C-MYC + cases, 1 showed CIN2+. Of
the 143 TERC-/C-MYC-cases, 4 (2.8%) CIN2+ cases
were confirmed by histological evaluation. A correlation
between the amplifications of TERC and C-MYC was
observed, with a correlation index of 0.506 (p < 0.01).
The association between TERC and C-MYC amplification
patterns and histological grades
We evaluated amplification patterns using the data of
TERC and C-MYC positive cases (Table 4). From the
TERC and C-MYC statistics, we found that the percentage
of abnormal nuclei was significantly higher in the CIN2+
group than in the normal/CIN1 group (21.1 vs. 10.2 for
TERC, p < 0.05; 20.9 vs. 6.2 for C-MYC, p <0 . 0 5 ) .T h e
most frequently observed TERC abnormal GCN was 3-6
(83.2% for the CIN2+ group; 97.7% for the normal/CIN1
group). The CIN2+ lesions showed more GCN ≥ 7 cells
than did the normal/CIN1 lesions (16.8% vs. 2.3%, p <
0.05). Cells with a TERC: CEP3 ratio of 1 were observed in
26.9% of the CIN2+ lesions and 33.8% of the normal/CIN1
lesions. The percentage of cells with a TERC: CEP3 ratio
greater than 1 was higher in CIN2+ lesions than in nor-
mal/CIN1 lesions (69.1% vs. 61.0%, p < 0.05). For C-MYC,
the percentage of cells with GCN = 3-6 was 97.0% for
CIN2+ lesions and 98.3% for normal/CIN1 lesions. The
percentage of cells with GCN ≥ 7 was 3.0% for CIN2+
lesions and 1.7% for normal/CIN1 lesions, and there was
no significant difference between these two histological
categories (p > 0.05).
Diagnostic performances of the TERC test and the C-MYC
test for the detection of CIN2+
To assess the performance of the TERC test and the C-
MYC test for evaluating high-grade cervical lesions, we
calculated the sensitivity, specificity, PPV, NPV, accuracy
and Youden’s index of cytological analysis and FISH test
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Page 6 of 12Figure 3 ROC and DFI curves for aberrant cell percentage and maximum GCN of TERC and C-MYC gain for CIN2+ diagnosis. A: Plots of
sensitivity vs. 1-specificity at cut-off values of the percentage of aberrant cells and of maximum GCN for the TERC and C-MYC tests. B: Plots of
DFI vs. cut-off values of the percentage of aberrant cells of the TERC and C-MYC tests. C: Plots of DFI vs. cut-off values at maximum GCN of the
TERC and C-MYC tests. In A, B and C, blue diamonds indicate the results of TERC gain at cut-off values of aberrant cell percentage ranging from
0% to 100%; pink squares indicate the results of C-MYC gain at cut-off values of aberrant cell percentage ranging from 0% to 100%; orange
diamonds indicate the results of TERC gain at cut-off values of GCN ranging from 1 to 23; slate green squares indicate the results of C-MYC gain
at cut-off values of GCN ranging from 1 to 13.
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nostic characteristics for a combined TERC and C-MYC
test (scenario 1: both markers amplified = positive test;
scenario 2: one of the markers amplified = positive test)
are also included. We chose ASCUS+, which showed
84.0% sensitivity and 64.3% specificity, as the cut-off for
cytological analysis. The diagnostic characteristics of the
TERC and C-MYC tests used separately or in combination
were calculated. Regarding the cut-off values, TERC +
determined as ≥ 5% aberrant TERC cells and C-MYC +
determined as ≥ 3% aberrant C-MYC cells.
In comparison with cytological analysis, the TERC test
showed higher sensitivity (90.0% vs. 84.0%) and specifi-
city (89.6% vs. 64.3%). The accuracy and Youden’si n d e x
of the TERC test were higher than those of cytological
analysis (89.7% vs. 68.3%, 79.6% vs. 48.3%, respectively).
In comparison with cytological analysis, the C-MYC test
showed lower sensitivity (80.0% vs. 84.0%) but higher
specificity (77.7% vs. 64.3%). The accuracy and Youden’s
index of the C-MYC test were higher than those of
cytological analysis (78.2% vs. 68.3%, 57.7% vs. 48.3%,
respectively). In comparison with the TERC test, the C-
MYC test showed lower sensitivity (80.0% vs. 90.0%)
and specificity (77.7% vs. 89.6%). If we combined the C-
MYC and TERC tests and considered one of the mar-
kers amplified to be positive, the sensitivity increased
from 90.0% to 92.0%, the specificity decreased from
89.6% to 72.0%, the accuracy decreased from 89.7% to
76.1% and Youden’s index decreased from 79.6% to
64.0%. If we considered both of the markers amplified
to be positive, the sensitivity decreased from 90.0% to
78.0%, the specificity increased from 89.6% to 95.3%, the
accuracy increased slightly from 89.7% to 91.8% and
Youden’s index decreased from 79.6% to 73.3%.
Discussion
Although liquid-based cytology is the procedure most
often used for cervical cancer screening, it has limitations
related to subjectivity and relative insensitivity. The high-
risk HC2 HPV DNA test is sometimes performed
because of its advantages of high sensitivity and NPV.
However, most women infected with HPV will eliminate
the virus within 1-2 years, and only a very small percen-
tage of them will progress to high-grade diseases. The
HPV DNA test is therefore a diagnostic method with
high sensitivity but low specificity, particularly for
younger, sexually active women [19,20]. It is now
accepted that the integration of high-risk HPV into the
Table 1 TERC and C-MYC positivity rates for various cytological diagnoses
Cytological diagnosis Case no. TERC positive C-MYC positive
Case no. % P Case no. % P
NILM 132 11 8.3 29 22.0
ASC-US 50 10 20.0 13 26.0
LSIL 21 11 52.4 12 57.1
ASC-H 14 9 64.3 6 42.9
HSIL 23 21 91.3 20 87.0
SCC 3 3 100.0 3 100.0
NILM vs. ASC/LSIL < 0.01* < 0.01*
ASC/LSIL vs. HSIL/SCC < 0.01* < 0.01*
LSIL/lower vs. HSIL/higher < 0.01* < 0.01*
† ASC includes ASC-US and ASC-H
*P < 0.05: statistically significant difference between 2 categories
Table 2 TERC and C-MYC positivity rates for various histological diagnoses
Histological diagnosis Case no. TERC positive C-MYC positive
Case no. % P Case no. % P
Normal 164 15 9.2 34 20.7
CIN1† 29 5 17.2 9 31.0
CIN2 21 16 76.2 15 71.4
CIN3 22 22 100.0 18 81.8
SCC 7 7 100.0 7 100.0
Normal vs. CIN1 > 0.05 > 0.05
CIN1 vs. CIN2+ < 0.01* < 0.01*
Normal/CIN1 vs. CIN2+ < 0.01* < 0.01*
† CIN1 includes lesions previously classified as mild dysplasia, koilocytotic atypia, koilocytosis and flat condyloma
* P < 0.05: statistically significant difference between 2 categories
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cervical carcinogenesis, and this phenomenon can not
only be observed in high-grade lesions but also in a pro-
portion of low-grade lesions [21,22]. The HPV DNA test
is incapable of distinguishing HPV physical status (episo-
mal vs. integrated) and is therefore not effective for iden-
tifying which patients with H P Vi n f e c t i o n sa r el i k e l yt o
have a CIN2+ lesion. According to the WHO guideline
[23] and the 2006 consensus guidelines of the American
Society for Colposcopy and Cervical Pathology (ASCCP)
[24], the recommendation for CIN1 cases is to undergo
follow-up examinations at defined intervals, whereas the
recommendation for CIN2/3 cases is to undergo immedi-
ate treatment for the prevention of progression to carci-
noma. In view of the limitations of the currently used
screening methods, more accurate and reliable predictive
biomarkers are needed to complement morphologically
based differential diagnostic methods. For the differential
diagnosis of low- vs. high-grade lesions, the change of the
biomarker should ideally be an early event in cervical car-
cinogenesis that occurs in precancerous lesions.
Amplification of oncogenes is commonly observed in
cervical precancerous lesion. It is a fairly early event in
cervical carcinogenesis. Researchers have applied FISH
probes to TERC and C-MYC, the two most frequently
observed amplified oncogenes in cervical precancerous
lesions as detected by CGH studies, for cytological spe-
cimen analysis. Heselmeyer et al. (2003) [25] applied a
FISH probe set to cervical cytological specimens and
found that the TERC gain cell counts and the maximum
TERC copies was correlated with the severity of cervical
lesions. After a follow-up of 1 to 3 years, the percentage
of TERC amplified cases increased from 52% to 96%
[26]. Sokolova et al. (2007) [27] applied a TERC-MYC-
HPV probe-mix to Thinprep slides and found that
LSIL/HSIL cytological specimens with underlying CIN2/
3 showed positive FISH test results in more than 80%
cases at a cut-off value of 4 or more double-positive
cells (HPV and TERC/MYC aberrations). Andersson et
al. (2009) [28] applied a TERC-MYC-HPV probe-mix to
Thinprep slides by a similar procedure but using differ-
ent enumeration methods and cut-off values. All cells
on the slides were enumerated, including HPV-positive
and HPV-negative cells. This procedure increased the
s e n s i t i v i t yb yi n c l u d i n gt h eH P V - n e g a t i v ec e l l sw i t h
oncogene amplification. The cut-off value of 9 cells with
more than two TERC copies in a whole slide scan
excluded the effect of HPV and MYC, and the cut-off
value of the TERC test appeared to be higher than the
Table 3 Cervical test positivity rates for various clinical groups
Cytological/histological diagnosis TERC positive cases [% (positive/total)] C-MYC positive cases [% (positive/total)]
NILM-negative 7.3 (8/109) 19.3 (21/109)
NILM-CIN1 0.0 (0/15) 33.3 (5/15)
NILM-CIN2+ 37.5 (3/8) 37.5 (3/8)
ASCUS-negative 12.8 (5/39) 23.1 (9/39)
ASCUS-CIN1 14.3 (1/7) 14.3 (1/7)
ASCUS-CIN2+ 100.0 (4/4) 75.0 (3/4)
LSIL-negative 18.2 (2/11) 36.4 (4/11)
LSIL-CIN1 75.0 (3/4) 50.0 (2/4)
LSIL-CIN2+ 100.0 (6/6) 100.0 (6/6)
ASC-H-negative 0.0 (0/3) 0.0 (0/3)
ASC-H -CIN1 0.0 (0/2) 0.0 (0/2)
ASC-H -CIN2+ 100.0 (9/9) 66.7 (6/9)
HSIL-negative 0.0 (0/2) 0.0 (0/2)
HSIL-CIN1 100.0 (1/1) 100.0 (1/1)
HSIL-CIN2+ 100.0 (20/20) 95.0 (19/20)
SCC-CIN2+ 100.0 (3/3) 100.0 (3/3)
Table 4 Proportions of TERC/C-MYC amplification types
in cervical disorders
TERC positive C-MYC positive
Histological diagnosis CIN2+ Normal/CIN1 CIN2+ Normal/CIN1
Case no. 45 20 40 43
Abnormal nuclei (no.) 963 213 854 293
Abnormal nuclei (%) 21.1 10.2 20.9 6.2
Distribution of GCN (%)
3 copies 27.7 55.9 48.0 49.5
4 copies 31.9 25.4 35.5 39.9
5 copies 16.5 10.8 9.6 7.2
6 copies 7.1 5.6 3.9 1.7
≥ 7 copies 16.8 2.3 3.0 1.7
Distribution of TERC: CEP3 ratios (%)
< 1 4.0 5.2
= 1 26.9 33.8
> 1 69.1 61.0
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Page 9 of 12cut-off value of Sokolova et al., thereby increasing the
specificity of the FISH test.
The procedures for specimen processing and signal enu-
meration in our study differed somewhat from those of
Sokolova et al. (2007) and Andersson et al. (2009). In our
study, the slides for enumeration were prepared with cell
suspension drops from residual Thinprep PreservCyt
(Cytyc) cytological specimens. The cells were pre-treated
with collagen B and deionized water and were thereby dis-
persed and enlarged. Because the cells were evenly mixed,
the possible selection bias of enumeration vision was lim-
ited. The TERC probe and C-MYC probe were applied
separately on two slides, in contrast to the two studies
above. Regarding the comparison of enumeration meth-
ods, Sokolova et al. (2007) analyzed the entire surface area
of each slide in most cases. However, when there was a
large number of HPV-positive cells per slide, the first 100
HPV-positive cells were analyzed and the number of
HPV-positive cells on a whole slide was extrapolated from
the percentage of surface area occupied by the cells.
Andersson et al. (2009) enumerated the signals by screen-
ing and counting the entire slide visually; an average of
2320 nuclei per slide (range: 232 to 4996 nuclei) were
counted. Enumerating cells on a whole slide might be
time-consuming and tedious. To achieve rapid and accu-
rate screening for clinical usage, we enumerated only the
first 100 cells on each slide and then screened the whole
slide. The time cost for signal enumeration of a slide is
determined by the number of cells on a whole slide and
the complexity of hybridization patterns. It usually takes
30 to 60 min to evaluate both the TERC and C-MYC sig-
nals for one patient.
The cut-off value we used for CIN2+ diagnosis is 5% or
more aberrant TERC cells, which is higher than the cut-
off values used in the two studies above and is also higher
than the cut-off value of ≥ 2.5% cells with more than 2
TERC signals used by Heselmeyer et al. (2003) [25].
However, the cut-off value we used is consistent with
that used in a multicenter study in China, and the mean
TERC test cut-off value determined for all of the partici-
pating centers was 6.4 ± 2.3% [18]. Regional and ethnic
differences were not ruled out for cut-off value differ-
ences. Using this TERC test cut-off value, our study
showed specificity values similar to those of Andersson et
al. (89.6% and 83.9%, respectively) and higher sensitivity
(90.0% and 78.7%, respectively) for CIN2+ diagnosis. As
possible cut-off value choices for the C-MYC test, the
values of ≥ 3% and ≥ 5% C-MYC gain cells showed simi-
lar AUC (0.8) and DFI (0.3) values. We chose ≥ 3% C-
MYC gain cells as the cut-off value because of its higher
sensitivity. Using this cut-off value, the C-MYC test
showed a sensitivity of 80.0% and a specificity of 77.7%.
The sensitivity and specificity of C-MYC would be simi-
lar to those of Andersson et al. if one used a cut-off value
of ≥ 5% aberrant C-MYC cells (66.0% vs. 66.0%, and
94.8% vs. 87.1%, respectively).
High-level amplifications have certain indication roles
for advanced-grade precancerous lesions. Compared with
other types of solid tumors, cervical cancer has a relatively
low-level of amplification, usually at 3 to 6 copies, and a
minority of the nuclei have a GCN > 20. Tu et al. [17]
found primarily TERC amplification patterns of 3 to 4
copies in the normal/CIN1 group, whereas in the CIN2+
group, the percentage of amplification patterns of 5 copies
and 6 copies were 10.2% and 54.6%, respectively. In our
study, we detected a SCC case with a TERC GCN of 22
and a CIN2 case with a C-MYC GCN of 12. We found
that the percentage of abnormal nuclei increased with the
severity of disease for both TERC and C-MYC (p < 0.05).
The CIN2+ group showed more high-level TERC amplifi-
cations (GCN ≥ 7) than did the normal/CIN1 group. How-
ever, the C-MYC amplification patterns are similar
between the normal/CIN1 and CIN2+ lesions. Although
GCN is an indicator for CIN2+ diagnosis, the combined
sensitivity and specificity of GCN is lower than that of
aberrant cell percentage for CIN2+ diagnosis.
TERC amplification patterns become more diverse as
histological grades increases. The formation of isochromo-
some 3q is frequently observed in cervical carcinogenesis.
In CGH studies, gain of 3q and loss of 3p were usually
observed simultaneously in cervical cancer. In the study by
Kirchhoff et al. (1999) [6], none of the 29 invasive cancers
Table 5 Comparison of cytological analysis and the FISH test for CIN2+ diagnosis
Test method Cytological analysis FISH test
Cut-off value† ASCUS+ TERC+ C-MYC+ TERC + and C-MYC+ TERC + or C-MYC+
Sensitivity, % (95%CI) 84.0 (73.8-94.2) 90.0(81.7-98.3) 80.0 (68.9-91.2) 78.0 (66.5-89.5) 92.0 (84.5-99.5)
Specificity, % (95%CI) 64.3(57.5-71.0) 89.6(85.3-93.9) 77.7 (71.8-83.6) 95.3 (92.3-98.3) 72.0 (65.7-78.3)
PPV, % (95%CI) 37.8(28.8-46.9) 69.2(58.0-80.5) 48.2 (37.5-59.0) 81.3 (70.3-92.3) 46.0 (36.2-55.8)
NPV, % (95%CI) 93.9(89.9-98.0) 97.2(94.8-99.6) 93.8 (90.1-97.5) 94.4 (91.2-97.6) 97.2 (94.5-99.9)
Accuracy, % (95%CI) 68.3(62.5-74.2) 89.7(85.9-93.5) 78.2 (73.0-83.4) 91.8 (88.4-95.3) 76.1 (70.7-81.5)
Youden’s index, % (95%CI) 48.3(31.3-65.2) 79.6(67.0-92.3) 57.7 (40.7-74.8) 73.3 (58.8-87.5) 64.0 (50.2-77.8)
† Cut-off value: ASCUS + determined as ASCUS or higher. TERC + determined as ≥ 5% aberrant TERC cells among all of the cells observed. C-MYC + determined
as ≥ 3% aberrant C-MYC cells among all of the cells observed
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Page 10 of 12analyzed showed an entire extra chromosome 3. A CEP3
probe was therefore used to evaluate the relationship
between TERC amplification and polyploidy. A TERC:
CEP3 ratio > 1 suggested isochromosome formation in a
cell. Cells with a TERC: CEP3 ratio > 1 accounted for
61.0% of the cells in the normal/CIN1 group and 69.1% of
the cells in the CIN2+ group. A TERC: CEP3 ratio of 1
was observed in 33.8% of the cells in the normal/CIN1
group and 26.9% of the cells in the CIN2+ group. The
TERC: CEP3 ratio appears to be higher in the CIN2+
group than in the normal/CIN1 group, and the formation
of an isochromosome provides a reasonable explanation
for this observation.
In comparison with cytological analysis, the TERC test is
suitable for CIN2+ diagnosis because of its high sensitivity
(90.0%) and its optimal combination of sensitivity and spe-
cificity (Youden’s index = 79.6). The C-MYC test is not
suitable for cancer screening because its sensitivity and
specificity are lower than those of the TERC test (80.0%
vs. 90.0% and 77.7% vs. 89.6%, respectively). When we
combined the C-MYC and TERC tests and considered
one of the markers amplified to be positive, the sensitivity
increased slightly from 90.0% to 92.0%, while the specifi-
city decreased greatly from 89.6% to 72.0%. The C-MYC
test showed marginally increased sensitivity for screening
but reduced specificity.
T h es p e c i m e n su s e di nt h ep r e s e n ts t u d yw e r ep r i m a r -
ily obtained from a population-based screening program
in which residual cervical liquid-based specimens were
used for the FISH test of TERC and C-MYC amplifica-
tion and for the HC2 HPV DNA test. Patients with posi-
tive results (cytological analysis, TERC test, C-MYC test
or HC2 HPV DNA test) were recommended for colpo-
scopic examinations. Colposcopy-directed biopsy and
histological evaluation were performed if indicated. The
correlations among oncogene amplification, HPV infec-
tion and cytological-histological results were analyzed,
and the design of an optimal strategy for cervical cancer
screening is discussed in a separate article (Shaomin
Chen, Yun Zhang, Yunbo Qiao, et al., manuscript in pre-
paration). To analyze the correlation between oncogene
amplification patterns and cytological/histological diag-
nosis in the present study, we chose all histologically con-
firmed cases, including 132 cases of NILM (including 84
HPV-positive cases and 48 HPV-negative cases; the 48
HPV-negative cases included 1 TERC+/C-MYC + case, 2
TERC+/C-MYC- cases, 10 TERC-/C-MYC + cases and
35 TERC-/C-MYC- cases; the 35 TERC-/C-MYC- cases
were selected as a control group) and 55 cases of ASCUS
+. This choice accounts for the higher number of histolo-
gically normal cases than abnormal cases. For the facilita-
tion of the statistical analysis of amplification patterns,
another 56 ASCUS + cases were recruited from February
2011 to October 2011. Although the number of abnormal
cases is still rather small, the aberrant cells observed are
sufficiently numerous for data analysis and it is possible
to reach preliminary conclusions regarding the oncogene
amplification patterns in CIN2+ cases. We collected
detailed data (including contact information) from all of
the patients who underwent screening for long-term fol-
low-up. It is recommended that patients with negative
screening results undergo routine screening and that
patients with positive screening results undergo cytologi-
cal analysis, FISH test, HPV test, colposcopy and histolo-
gical evaluation at defined intervals.
The FISH test is suitable for clinical testing because of
its several advantages. It can be performed using resi-
dual cytological specimens without additional sampling.
The FISH test is a cell-based evaluation technique and
is therefore more sensitive than other methods such as
PCR and microarray-based analyses. The interpretation
of fluorescent signals is objective and repeatable and
does not rely heavily on highly trained personnel. We
were interest in possible reasons for the discrepancy
between FISH test results and cytological or histological
results. We reviewed the slides of the 4 NILM/TERC-/
CMYC- cases with underlying CIN2+ by screening the
whole slide and found that the aberrant cell percentages
were below the cut-off values and that the amplification
patterns were simple (3-4 copies). We also reviewed the
colposcopical and histological images from these cases
and found that most of them were focal CIN2+ cases;
therefore, sampling omissions could not be ruled out.
The preliminary results of this study indicate that
TERC amplification is a clinically applicable genetic
approach for cervical lesion diagnosis because of its high
sensitivity and optimal combination of sensitivity and
specificity. The C-MYC test cannot be used for screen-
ing because of its low sensitivity and because it does not
result in increased specificity when used in combination
with the TERC test. Compared to the C-MYC test, the
TERC test shows more high-level amplification copies
and more diverse amplification patterns in high-grade
lesions. However, the sensitivity of the TERC test is
l o w e rw h e nu s i n gac u t - o f fv a l u ef o rt h eG C Nt h a nf o r
the cell percentage. Further investigation of the possible
application of GCN for prognosis of cervical neoplasia is
needed.
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